Clone:
REAL702
Type of antibody:
Releasable antibodies, Primary antibodies, Recombinant antibodies
Applications:
FC
Alternative names:
MS4A1, B1, Bp35, CVID5, LEU-16, MS4A2, S7, Ly-44

Specifications for CD20 Antibody, anti-human,
REAlease
®

Overview

Clone REAL702 is an antibody fragment derived from the full CD20 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
Clone REAL702 recognizes the CD20 antigen, a non-glycosylated transmembrane protein of 33–37 kDa that is expressed on B lineage cells from the pre–B cell stage to the B cell lymphoblast stage. The antigen is further expressed on most malignant B cells. CD20 is not found on early B cell progenitors or plasma cells. Oligomers of CD20 form a Ca2
+
channel and might function in the regulation of local responses during B cell activation.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

MS4A1, B1, Bp35, CVID5, LEU-16, MS4A2, S7, Ly-44

Detailed product information

Technical specifications

CloneREAL702
Clonalitymonoclonal
Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable antibodies, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenCD20
Alternative names of antigenMS4A1, B1, Bp35, CVID5, LEU-16, MS4A2, S7, Ly-44
Distribution of antigenB cells, dendritic cells, lymphocytes, cancer stem cells

References for CD20 Antibody, anti-human,
REAlease
®

Publications

  1. Lamprecht, B. et al. (2008) Aberrant expression of the Tʜ2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 112(8): 3339-3347
  2. Maxwell, S. A. et al. (2009) 14-3-3zeta J. Biol. Chem. 284(33): 22379-22389
  3. Countouriotis, A. et al. (2002) Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 20: 215-229
  4. Polyak, M. J. and Deans, J. P. (2002)
    CD20 Workshop Panel report: in Mason, D.
    et al.
    (eds.): Leucocyte typing VII,
    Oxford, Oxford University Press

Seems like you are coming from USA!
Do you want to visit our website in your country?